A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected,
tumor-reactive TIL product, in patients with advanced solid malignancies.